Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Angeline GinzacIoana MolnarXavier DurandoThibault De La Motte RougeThierry PetitVeronique D'HondtMario CamponeNathalie Bonichon-LamichhaneLaurence Venat BouvetChristelle LevyPaule AugereauBarbara PistilliOlivier ArseneChristelle JouannaudSuzanne NguyenAnne CayreLucie TixierCéline Mahier Ait OukhatarJean-Marc NabholtzFrédérique Penault-LlorcaMarie-Ange Mouret-ReynierPublished in: Breast cancer research and treatment (2024)
NCT02339532 (registered on 14/12/14).